F. HOFFMANN-LA ROCHE AG;VIB VZW;LIFE SCIENCES RESEARCH PARTNERS VZW
发明人:
申请号：
ARP120103188
公开号：
AR087713A1
申请日:
2012.08.29
申请国别(地区):
AR
年份:
2014
代理人:
摘要：
Refers to a Pharmaceutical composition comprising an inhibitor of angiogenesis, such as bevacizumab for the treatment of a patient suffering from cancer, based on the genotype of the VEGF Promoter Gene and / or Gene VEGFR2.He further refers to a method to improve the effect of chemotherapy of a patient suffering from cancer, through the addition of an inhibitor of angiogenesis, such as bevacizumab, based on the genotype of the VEGF Promoter Gene and / or Gene VEGFR2.Claim 1: Method for determining whether a patient will be suitably treated with a Therapy that includes an angiogenesis inhibitor bevacizumab or comprising an Antibody that binds essentially the same epitope of VEGF that bevacizumab,Said method comprising: (a) determine in a sample derived from a patient suffering from cancer in the rs699946 genotype polymorphism (SEC ID no. 1)And (b) to identify whether a patient will be more or less conveniently treated with an inhibitor of angiogenesis Therapy with bevacizumab or comprising an Antibody that binds essentially the same epitope of VEGF that bevacizumab based on the genotype,In the presence of each allele polymorphism in the rs699946 (SEC ID no. 1) indicates an increased likelihood that the patient is more properly treated, or the presence of the G allele polymorphism in the rs699946 (SEC ID no. 1) indicates an increased likelihood that d Icho Patient less properly treated.Se refiere a una composición farmacéutica que comprende un inhibidor de la angiogénesis, tal como bevacizumab, para el tratamiento de un paciente que sufre de un cáncer, basado en el genotipo del gen del promotor de VEGF y/o del gen VEGFR2. Se refiere además a un método para mejorar el efecto del tratamiento de quimioterapia de un paciente que sufre de cáncer, mediante la adición de un inhibidor de la angiogénesis, tal como bevacizumab, basado en el genotipo del gen del promotor de VEGF y/o del gen VEGFR2. Reivindicación 1: Método para determinar si un paciente resultará convenienteme
